Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 299

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 8
Chunk 299
---
 equity (deficit)

    Current liabilities:

    Accounts payable
     
    $
    4,367

    $
    3,684

    Accrued compensation

    6,589

    11,519

    Accrued research and development expenses

    7,984

    17,364

    Deferred revenue

    95,092

    77,833

    Other current liabilities

    20,542

    31,826

    Total current liabilities

    134,574

    142,226

    Deferred revenue – long-term

    —

    37,562

    Operating lease liabilities – long-term

    29,914

    45,693

    Liability related to the sale of future revenues – long-term

    38,624

    34,623

    Other long-term liabilities

    3,269

    4,631

    Total liabilities

    206,381

    264,735

    Commitments and contingencies (Note 9)

    Stockholders’ equity (deficit):

    Common stock—$0.0001 par value, 500,000 shares authorized as of December 31,   2024 and 2023, respectively; 5,859 and 4,258 shares issued and outstanding   as of December 31, 2024 and 2023, respectively

    1

    —

    Additional paid-in capital

    1,957,261

    1,870,123

    Accumulated other comprehensive (loss) income

    8

    (204
    )

    Accumulated deficit

    (2,054,553
    )

    (1,969,150
    )

    Total stockholders’ equity (deficit)

    (97,283
    )

    (99,231
    )

    Total liabilities and stockholders’ equity (deficit)
     
    $
    109,098

    $
    165,504

 See accompanying notes to the consolidated financial statements.

99

Atara Biotherapeutics, Inc. 

Consolidated Statements of Operations and Comprehensive Loss 

(In thousands, except per share amounts)

    Years Ended December 31,

    2024

    2023

    Commercialization revenue
     
    $
    128,940

    $
    7,886